Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study
暂无分享，去创建一个
A. Hagenbeek | G. Salles | A. López-Guillermo | R. Bouabdallah | L. Xerri | O. Casasnovas | P. Feugier | H. Tilly | C. Sebban | C. Haioun | A. Delmer | S. Leppä | A. Sonnet | R. Pettengell | P. Brice | J. Seymour | F. Offner | L. Pedersen | J. Catalano | P. Soubeyran | J. Estell | D. Belada | D. Caballero | D. Simpson | G. Milone | C. Fermé | M. G. Silva | I. Tanin